Prolong Pharmaceuticals, a clinical stage biopharmaceutical company focusing on developing products to treat several diseases and their debilitating comorbidities associated with reduced quality of life, increased medical cost, and significant mortality, announced today that Glenn Kazo, its president and chief operating officer, will present an overview of the company at the 36th Annual J.P. Morgan Healthcare Conference in San Francisco.
This author has yet to write their bio.Meanwhile lets just say that we are proud ProlongAD01 contributed a whooping 29 entries.
Entries by ProlongAD01
Prolong Pharmaceuticals announced today that it has completed enrollment in its Phase II study to evaluate SANGUINATE® in the treatment of vaso-occlusive crisis in patients with sickle cell disease (SCD). SANGUINATE® is a first-in-class oxygen-delivery agent that is in development to treat localized and systemic hypoxia…
An Interview with Glenn Kazo, President from Prolong Pharmaceuticals. With over 25 years of experience, Glenn Kazo is the President and Chief Operating Officer of Prolong Pharmaceuticals LLC, a privately held company with portfolio of hematology and oncology products in clinical development. Over the last decade Kazo has been very active in the advancement of Biosimilars and BioBetters, both as an industry speaker and in leading several drug development programs…
SOUTH PLAINFIELD, N.J., May 2, 2017 /PRNewswire/ — SANGUINATE™, the only investigational biopharmaceutical product currently in clinical development for the treatment of multiple comorbidities of sickle cell disease (SCD), is effective in returning red blood cells to a more normal morphology (shape) in patients experiencing vaso-occlusive crisis (VOC)…
Unique activity Noted in Drug: Prolong Pharmaceuticals, LLC, a biopharmaceutical company dedicated to developing products to treat several diseases and their debilitating comorbidities announced today that it has presented data on the toxicology, pharmacokinetic and pharmacodynamic profile of its novel anti-neutropenia drug, ANF-RHO.
Prolong Pharmaceuticals presented at the 2016 Society for Blood Advancement (SABM) meeting in Grand Rapids Michigan. The Workshop entitled Clinical Use of SANGUINATE in Patients for Whom Blood is Not an Option provided an overview of the use of SANGUINATE followed by the presentation of a case report of a patient who received SANGUINATE for life threatening anemia.
Prolong Pharmaceuticals Hosts Lunch & Learn and Announces Launch of SCDTrialMap.com at the 44th Annual Convention of the Sickle Cell Disease Association of America.
Prolong Pharmaceuticals joins other leading patient advocacy groups, researchers, clinicians, policymakers, industry, and foundations in a collective effort to improve sickle cell disease (SCD) care, early diagnosis, treatment, and research, both in the United States and globally…
NY/NJ CEO is an off-the-record networking and educational forum for leading executives in life sciences, offering exclusive access to key decision makers who influence …
Background: Patients who cannot receive blood transfusions in the presence of severe anemia can sustain significant morbidity and mortality. Religious beliefs and hemolytic reactions are the most common reasons for not transfusing a patient. Pegylated bovine carboxyhemoglobin (PEG-HbCO) has been used in 5 such patients
1 Cragwood Road, Suite 203
South Plainfield, NJ 07080 USA
Primary Mailing Address:,
R&D, Labs, Manufacturing
300 Corporate Court, Suite B
South Plainfield, NJ 07080 USA